SARS-CoV-2 genomic surveillance in Geneva: bi-weekly update

Highlights:

- In the first two weeks of January, we have seen a decrease in the number of tests, and a decrease in the positivity rate not recorded since approximately November 2021 (Figure 1).
- Since 1 January 2023, only 30 samples from the Geneva area will be sequenced weekly. Statistics and trends published by our laboratory biweekly might give some hints about the local epidemiology but are not optimally representative.
- For weeks 1 and 2 only n=16 and n=5 Geneva samples were sequenced, respectively.
- BQ.1/BQ.1.1 sublineages still represent most of the sequenced samples.
- No XBB.1.5 sublineages were found in weeks 1 and 2.
- The monitoring of the 346T mutation by PCR was stopped, as the proportion had already attained 92.6% in week 1 (low sample number)(Figure 3)*. 
- For weeks 1 and 2 respectively, 2/16 and 0/5 sequenced samples displayed the wildtype amino acid 346R.

More information *:
From week 45/2022 to week 1/2023, the laboratory performed the S:346T mutation screening (one batch per week; one batch usually contained samples from the week before). The prevalence of the 346T mutation had been increasing steadily to up to 92.6% in week 1, 2023 (Figure 2). It was therefore decided to stop the monitoring. This mutation, among others, is found on several Omicron sub-variants, and is phenotypically associated with immune escape, notably regarding mAb treatments.
**Figure 1:** Total number of SARS-CoV-2 tests performed at the HUG per day and over 5 weeks (PCR and antigenic tests). The positivity rate is displayed as a red curve. **Bottom left:** SARS-CoV-2 positive tests over 7 sliding days. **Bottom right:** mean SARS-CoV-2 tests performed over 7 sliding days.
Figure 2: SARS-CoV-2 lineages identified by whole-genome sequencing at HUG from samples (Ct-value ≤32) collected from Geneva residents (Sentinella specimens excluded). A total of 440 sequences were included in this analysis. Bottom Left: Percentage of SARS-CoV-2 sequenced samples with the S:R346T/S.

Figure 3: Number and proportion of SARS-CoV-2 screened samples with and without the 346T mutation. Non-interpretable samples are displayed as “Non-INT”.

Laurent Kaiser, Samuel Cordey, Manuel Schibler, Yerly Sabine and Iris Najjar for the HUG and the Geneva Centre for Emerging Viral Diseases.
Emma Hodcroft for the Geneva Center for Emerging Viral Diseases.
Geraldine Duc, for the Geneva Cantonal Physician team.
The laboratory of virology of the Geneva University Hospitals as a sentinel site for the Geneva area

The number of tests (PCR and antigen tests) performed at the Geneva University Hospitals represented around 59.7% (890/1491), and 64.1% (742/1158) of the total number of tests performed in the canton of Geneva during weeks 1 and 2 of 2023, respectively. Roughly 56.6% (128/226) and 54.3% (75/138) of the positive specimens collected in the Geneva area were processed at HUG during weeks 1 and 2, respectively. Specimens analyzed at the HUG originate from ambulatory and hospitalized patients and symptomatic and/or asymptomatic healthcare workers.

The number of positive tests in the canton and the total number of tests done during the surveilled weeks are available on the website of the Federal Office of Public Health (COVID-19 Suisse | Coronavirus | Dashboard (admin.ch)).

During weeks 1 and 2 in the canton of Geneva, the total number of tests, confirmed cases, and positivity rate decreased compared to the previous weeks to very low levels. In week 3, we might start seeing a stabilization of the numbers at this low level.

Methods and collaborations

Of note, the laboratory had introduced, from week 45 2022 to week 1 2023, the screening of the S:346T mutation using the SARS Spike R346T kit (TIB Molbiol).

WGS is conducted in close collaboration with the Health 2030 Genome Center in Geneva and Philippe Le Mercier from the Swiss Institute of Bioinformatics. The national genomic surveillance program has been ongoing in Switzerland since March 1, 2021, and includes specimens collected at the HUG with a Ct-value ≤32. In some instances, sequencing can be done on specimens sent by other laboratories in Switzerland within the surveillance program or by request of the cantonal physician team. Phylogenetic analysis data are produced by Nextstrain in collaboration with Richard Neher’s group at the University of Basel and analyzed by Emma Hodcroft, from the Geneva Centre of Emerging Viral Diseases and the University of Geneva. In addition, partial Sanger sequencing may be done by our laboratory.

Geographic distribution, transmission advantage estimates and detailed numbers of available sequences over time in the canton of Geneva are available on the CoVSpectrum platform, run by Tanja Stadler’s group at ETH Zurich.

These reports are produced in collaboration with the Geneva Cantonal Physician team, which provides information on epidemiological links. For epidemiological data, please refer to the report of the cantonal physician team.